Intermittent pneumatic compression in combination with low-molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery

2017 ◽  
Vol 115 (2) ◽  
pp. 181-185 ◽  
Author(s):  
Kevin Parry ◽  
Amir-Hossein Sadeghi ◽  
Sylvia van der Horst ◽  
Jan Westerink ◽  
Jelle P. Ruurda ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Esophageal Cancer ◽  
Low Molecular Weight Heparin ◽  
Intermittent Pneumatic Compression ◽  
Cancer Surgery ◽  
Low Molecular Weight ◽  
Thromboembolic Events ◽  
Esophageal Cancer Surgery ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Thalidomide and thrombosis

2007 ◽  
Vol 97 (06) ◽  
pp. 1031-1036 ◽  
Author(s):  
Ramzi El Accaoui ◽  
Wael Shamseddeen ◽  
Ali Taher
Keyword(s):  
Molecular Weight ◽  
Multiple Myeloma ◽  
Low Molecular Weight Heparin ◽  
Literature Search ◽  
Concomitant Administration ◽  
International Normalized Ratio ◽  
Low Molecular Weight ◽  
Thromboembolic Events ◽  
Multivariate Logistic Regression ◽  
Venous Thromboembolic

SummaryWith the increase in the number of reports and trials on the use of thalidomide as a part of the treatment of different medical conditions, particularly multiple myeloma (MM), it was observed that this drug might be associated with an increase in the risk of venous thromboembolic (VTE) events. It was the objective of this study to assess this risk, to check whether it might be affected by the concomitant administration of other medications, specifically dexamethasone, and to study the effect of anticoagulation and anti-platelet medications. A literature search for articles describing the use of thalidomide and the resultant VTE events was performed, and 50 articles were reviewed. A sample consisting of 3,322 patients resembling the above-mentioned studies was designed, and multivariate logistic regression was conducted.While thalidomide, dexamethasone and their combination were found to significantly increase the risk of VTE events among MM patients by 2.6, 2.8 and eight times, respectively, “adequate” anticoagulation significantly reduced the risk. In conclusion, patients receiving thalidomide should be carefully monitored for thromboembolic events,and those receiving concomitantly dexamethasone or other chemotherapy should be followed even more closely. Administering prophylactic doses of low-molecular-weight heparin or warfarin with therapeutic International Normalized Ratio reduces the risk of thromboembolic events among MM patients.

The Current Status of Thromboprophylaxis after Trauma: A Story of Confusion and Uncertainty

2006 ◽  
Vol 72 (9) ◽  
pp. 757-763 ◽  
Author(s):  
George C. Velmahos
Keyword(s):  
Molecular Weight ◽  
Pulmonary Embolism ◽  
Standard Of Care ◽  
Current Status ◽  
Low Molecular Weight ◽  
Trauma Patients ◽  
Thromboembolic Events ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Calf Compression

It is difficult to support a standard of care for venous thromboprophylaxis after trauma when there is no convincing research that any of the currently used methods is consistently effective. Because many conclusions from the nontrauma literature have been misleadingly extrapolated to trauma patients, this review focuses exclusively on trauma articles. These articles present variable results. The rates of deep venous thrombosis and pulmonary embolism are widely different even among similar trauma populations. The heparin-unfractionated or low-molecular-weight and calf compression methods fail to show a reproducible effect in decreasing venous thromboembolic events. The current methods of venous thromboprophylaxis after trauma are inadequate and further research in this area is direly needed.

scholarly journals USE OF BEMIPARIN IN PATIENTS UNDERGOING MAJOR SURGERY FOR ESOPHAGEAL AND GASTRIC CANCER

2017 ◽  
pp. 104-111
Author(s):  
R. A. Khvavstunov ◽  
S. E. Tolstopyatov
Keyword(s):  
Gastric Cancer ◽  
Molecular Weight ◽  
Major Surgery ◽  
Low Molecular Weight ◽  
Thromboembolic Events ◽  
Low Molecular Weight Heparins ◽  
Short Term ◽  
Increased Risk ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

The purpose of our study is to evaluate our own experience in the use of low molecular weight heparins, in particular bemiparin, in a group of patients with an increased risk of venous thromboembolic events undergoing major surgery for esophageal and gastric cancer. The study presents a comparative analysis of these groups and short-term results of the use of bemiparin in cancer patients.

Sign in / Sign up

Export Citation Format

Share Document